Artelo Biosciences, Inc.
ARTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.73 | 0.27 | 0.02 | 0.03 |
| FCF Yield | -40.74% | -33.01% | -97.84% | -36.08% |
| EV / EBITDA | -1.81 | -2.22 | -0.13 | -1.41 |
| Quality | ||||
| ROIC | -341.37% | -84.33% | -52.85% | -61.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.88 | 0.79 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -1.74% | -2.49% | -30.40% | -41.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | 0.28 | 0.68 | 0.88 |
| Interest Coverage | 0.00 | 0.00 | -2,057.40 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |